0001493152-24-008950.txt : 20240306 0001493152-24-008950.hdr.sgml : 20240306 20240306084035 ACCESSION NUMBER: 0001493152-24-008950 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: enVVeno Medical Corp CENTRAL INDEX KEY: 0001661053 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330936180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38325 FILM NUMBER: 24724456 BUSINESS ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-261-2900 MAIL ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Hancock Jaffe Laboratories, Inc. DATE OF NAME CHANGE: 20151215 8-K 1 form8-k.htm
false 0001661053 0001661053 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 6, 2024

 

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-38325   33-0936180
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

70 Doppler

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

 

(949) 261-2900

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.00001 per share   NVNO   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On March 6, 2024, enVVeno Medical Corporation (“we,” “us,” “our,” or the “Company”) issued a press release announcing that positive topline efficacy data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve is being presented today at the 2024 American Venous Forum (AFV) Annual Meeting in Tampa, Florida. The press release is being furnished as Exhibit 99.1 to this report.

 

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our clinical trials, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A - Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Current Report.

 

Item 9.01 Financial Statements and Exhibits.

 

Set forth below is a list of Exhibits included as part of this Current Report:

 

Exhibit No.   Description
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENVVENO MEDICAL CORPORATION
   
Dated: March 6, 2024 /s/ Robert A. Berman
  Robert A. Berman
  Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

 

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))

 

74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points)

 

Average rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the VenoValve’s Clinically Meaningful Benefit

 

Company on Track to File Application Seeking VenoValve FDA Approval in Q4 2024

 

Company to Host Live Webcast with Presenting PI, Today, March 6th at 1:30 PM ET – Access the Webcast Here

 

IRVINE, Calif. – March 6, 2024 – enVVeno Medical Corporation (Nasdaq: NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the presentation of positive topline efficacy data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum (AFV) Annual Meeting in Tampa, Florida. The data being presented today shows that overall, 97% of the study patients receiving the VenoValve have shown clinical improvement as measured by revised Venous Clinical Severity Score (rVCSS), 74% of the study patients have improved the 3 or more rVCSS points needed to demonstrate the VenoValve’s clinically meaningful benefit, and the average amount of per patient improvement for patients showing clinically meaningful benefit is 8 points, more than two and a half times the amount of rVCSS improvement required by the U.S. Food and Drug Administration (FDA) to show that the VenoValve provides clinically meaningful benefit. All of the reported data was derived by comparing rVCSS patient evaluations at six months to baseline readings taken prior to VenoValve implantation. The Company will host a live webcast to discuss the results, today, March 6, 2024, at 1:30 PM ET (details below) – access it here.

 

“The results that we are seeing exceed our expectations and we are thrilled with both the number of patients whose Chronic Venous Insufficiency (CVI) is improving, and the amount of clinical improvement that we are seeing across our study population,” said Robert Berman, enVVeno Medical’s CEO. “A large portion of our patients are not only getting better, they are getting a lot better. This means that many of the study participants have progressed from having severe, debilitating CVI, to a much more mild form of the disease, or no disease at all. It is extremely gratifying to see widespread and dramatic improvements in patients that have no other effective treatment options.”

 

 

 

 

In assessing the benefit and risk of a novel technology such as the VenoValve, which addresses an unmet medical need, the FDA considers a variety of factors including whether a medical device provides a clinically meaningful benefit compared to existing technologies. Patients who were enrolled in the SAVVE study all showed little or no improvement after at least three months of conventional treatment with existing technologies (compression therapy, leg elevation, and wound care for venous ulcer patients). For severe CVI patients, an improvement in the rVCSS of 3 or more points is considered by the FDA to be evidence of clinically meaningful benefit.

 

The rVCSS is an objective grading system used by vascular specialists throughout the world to report clinical outcomes and responses to treatments for venous diseases such as CVI. The score consists of 10 categories graded from 0 to 3 and includes patient reported outcomes and physician assessments.

 

Severe CVI is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence and the Company estimates that there are approximately 2.5 million new patients each year in the U.S. that could be candidates for the VenoValve.

 

The FDA has asked the Company to collect a minimum of one year of data on all SAVVE patients prior to filing its PMA application seeking FDA approval, which the Company will have completed collecting in September of 2024. As of December 31, 2023, the Company had cash and investments of $46.4 million on hand, which should be sufficient capital to fund operations through an FDA decision on the VenoValve and the end of 2025.

 

The Surgical Anti-reflux Venous Valve Endoprosthesis (SAVVE) U.S. pivotal study for the VenoValve is a prospective, non-blinded, single arm, multi-center study of seventy-five (75) CVI patients enrolled at 21 U.S. sites. The presentation at AVF will be made by primary investigator Dr. Cassius Iyad Ochoa Chaar MD, MS, RPVI, Associate Professor of Surgery, Division of Vascular Surgery, Yale School of Medicine, the top enrolling site for the trial. To hear from patients in the SAVVE study, see examples of venous ulcer healing caused by the VenoValve, and learn more about the SAVVE pivotal trial, please visit enVVeno.com.

 

Webcast Details

 

The Company will host a webcast presentation to discuss the results for investors, analysts, and other interested parties today, March 6, 2024, at 1:30 PM ET. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, envveno.com, and will be archived for 90 days.

 

 

 

 

About enVVeno Medical Corporation

 

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company’s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently performing the final testing necessary to seek approval for the enVVe pivotal trial.

 

Cautionary Note on Forward-Looking Statements

 

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

 

###

 

INVESTOR CONTACT:

 

Jenene Thomas, JTC Team, LLC

NVNO@jtcir.com

(833) 475-8247

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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nvno-20240306.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nvno-20240306_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nvno-20240306_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-38325
Entity Registrant Name enVVeno Medical Corporation
Entity Central Index Key 0001661053
Entity Tax Identification Number 33-0936180
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 70 Doppler
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (949)
Local Phone Number 261-2900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol NVNO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://envveno.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm nvno-20240306.xsd nvno-20240306_lab.xml nvno-20240306_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NVNO", "nsuri": "http://envveno.com/20240306", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "nvno-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nvno-20240306_lab.xml" ] }, "presentationLink": { "local": [ "nvno-20240306_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://envveno.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://envveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-008950-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-008950-xbrl.zip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

!9H>R-[H>Q^S4*>B**DL5@H%/3@G;= E*KDD#&146D*W6QO-U"W$=<1H!166$8*L#CKS)$%\ZP$T-N?(L@529* MN)BSEDY-2J*ZA.U1&07( R'&8V)"!2:;4[7&9)QJAE#!N"00B1C2H%+LTD&( MO13 B2$MH;=^#JE6H"!F\V@ $%/QPD53"+D)Y:2>I5#I=A_02'& MAE0*6G9V/;)[P;'7-]F02L"E]L0_9PI:,*?H1N&(G%OX?O-F1"V==/S6DX2J M=7[M!=)'(KP@XX+79ATS)JEOP,UPREBCPV<(Y3^JPG$L<+>!CLTMH=G0Z8(9 MLNNM9K;, 0151@$"_GVX3'-@5'ZLX>>]*? J=J&2A//67&K(1\4JE1UO,;P7 M,]EZN41DDQVJ,%9%X3(;,-_"(JVXR:BR"%-MAAOKBYM>DRB*7L >CMPE$P]2-);'"I=>(T3*YJ9-M';9FOT/% 2)]IJB]IIPWH3-0#3ZO$8N2 MX-92\3ZKNB$O%ID*#GG,C(]US+O<*6@_>;?'#+J$BF;0;6EOU+HB0'\I]8/F M$=9%Y$PK+FZ83#GQDB)329:T& #4 =*Z&%'74B>:+%IH7!M\[),:U9U>ZSJ] MC@KI&[P!NY=W:JU4V2#-310%2D\LGHWA,HSCZ:/B,_ZA9JDE2W=.F:+KG@$CYQRP ?SOGNV$"C+20);"AVV3[VUGMZ M+GV[XP(9;'"SA- M>?X.XD#6'27,*Y/T>PN9B&L/]]NM^NN?)3@PQ.J&6T5<;=:93ZP[78M6M)+]C5WWD=LLEL%B$]UC% MV8U*!%DSW% M0 /T3@Z[5_WA6?\?AVZ*T]7J+XHYXVZ>$S5%IF67!JR0IB0$[D/5O6M+LJ&- MKED(\1,3,7[VV;",YQ).,(QNZBPSU%&B['BL0UI%PQ"[I;:V4F['/?)VE4^W MZ_:7G_MP,Z)_9D1T;=ZK'F,!0(\Y-XNKJ.RLH_W-E]LZKFP\T86EMV"[48+4 M2-B05Q8JAZ=VI_1;#%J?7B.Z M$FO"'FZ*AG+,0!Q.5LC,1I(8#:#$#/XJQ:Y;%N).,:+C@^6 JAM.SKC2^ZW+Y MO5 JITIXX[%&+3R4MN-5-=S?=(>KE6_0PG;5VQ]X7JM-.U*I*2:L2;1 M4>6XY"0UX:?].2,GZ)XX"=-BC7>D,L];MXRB>6,5\ZP^E;:EI>)==R&7GK4= MMT&2"\K8+5>JH=BY*\)[KE1Y.)N#D6/_W@9=I S:=>B3*IOZXL%:&:,N9-,H M+.-E-YFYV/_+($0:>Q%N4'&O GM0SY!F0>1R]5FFU/-TV3YW M[4 5_"U]&:91)U[Q$J]XJV/Z[=JM5?,SS(D$IS\H])QPSI"ZD)HK")>:RZ%T MAL^*AT+[$K2C^0T=Z*_RX$M7.%R82A&AFZGYPW\)HUBV'KFUU_' M-IV:._X:51@V[^.>W^;%Q7T774-E\^I8)5I1K-JX[D:J[UP&KWBPMUP]49-7 MMS8W'Z(B4!;?N4R3_W M)44EJ*.*=JM!,8*[?PV*B+**ZVG8D6IY\"MZ1>#73:A7QY+?,*_@!&H.M5MK M+%H!L@9K_1&=&$W&LX*$X<*@X&X8-O<#B"1RM33K3?;52T-P4H5)UK$YD1$3 M&3>@@2:YQTGP)B @K_ Q I.JG!KHPB5/7SML9S6O2(F('T@ >=2SUQGY)N\5 M)E5)L+995K4\N\Z>S#@+#+1W[]K6I)((%P;,=.;,R>V21(_:AW5U57 MMX[_,QU99,RX,!W[_9_Y3.Y/PFS=,4S[YOV?M5Z]U?KS/U7M>"BA&32UQ?O4 M4$JWDLU.)I/,I)AQ^$TV7RZ7LU-LD_(;5::)[0JY7#[[U_E93Q^R$4V;MI#4 MUMF\DV7:M^O'Q[?SIGUNF;&F^"2&HL.T<;[6?]EK*E,;+KG-Y5A M4U,XI4+^X"XX_!;S#M-U;?,(,V#(_CKIGBV:R^3VBZ99R:DM!@X?40DLQ)'V MTKE"NK ?&20MF!X;"'YG;ISQ#\2-]0ZLX;#ZCHJX;!B]BH\(P[%A.)K=6;6'/=\6S) M9\D0!R]C'027JT/#PUBC]E6[,V_%[/&8V4Y&=T;8J)0KYO93J%J,&E6-X/^. MI2DM5CW.^G]KQR,F*<'^:?;-,\?O4W7'ELR6Z43:=,0J9&I,CTBKH?YQG2O4KS_W_B@T/M1J%_ 7 M0D_2Z7MV+I:N$<7K"&K7(6KW'Z54FG=Z1.^]\C4#D0+8X;_:B-D&_%^>6O3F M>D MP1XPTD%DI*8-/)C582A.K99ML.E'-KO.@0';W\_G]AY I/T3H'#C.G\= MV )_?'CT@"$*U[TAY4Q<%ZZ5Y?/'$.K9 X9I("07P5#%%8#6C=UWC!D1H"_H%7;&\$XNB_C4]E%*U$3G0%*2#I73(/R$!N0 MA+&968DQ/D5,XWW*G([3Q;U\JJK$X#@;&_;1$R7*173"0JJZD)*D6;-1;!$& M,'&,PZ++A'J/AK0BU H)L!"U[%6&RDK:8]M)ARJ2F0HC%;R68 [>IX0YO&#Y!7 M;1XYP<)<+$\"N@V,6R$H]E3"3J7#%V\?C/LR> EC1F9LP.(S,NT?S/E#>BQ/ MFC!L^#J*_C(9 ]5;:)JO\H&U.\Y"WZJF:<=N:!Q1>M+4,F_L"M%!Z!D_(B/* M;TP[+1VW0G+SGWU'2F<$3U+5?_\KOY\[.LZZU>A0]S7/2Q.XT)%I@:W_ 02JK3"_,Q]@&"F+0U4#G"(K6M>S6/J"WJC% M/+JL3$Q##K%[[H]4[$7?X4!M'[L3B^JWI 0D$8YE&D!EBZK_/9_86+:*@ M(60AL9%UP9\1\+(Q^#:''?TYWOTEWKQZ! \#!#^W6Y?-AM:[K%TV>QN,9Z]9 M_]QM7;::/:W6;I#F7_7_UMH?FJ3>.3]O]7JM3GL#D2\$R'^A8FC:-]*Q=[5& MIIXAA=Q>J;R!".>BMFJC, OE^+33/=?\$=$_P;"FG"NIN"V=;CBZAS$ !L?7 M^CRF7$27WT^\WI?/YZ5A8#HA<>%1VVI20>:Z9C^(_DBZ71)?F_'>$>< 9%# MML$$ *0];DJ3":TYU8?4!D>NIDM$/%\NEC85\XW67@S>-6!@E[D.EV0'?R-# M&850C0E)V!BF)5R]9L:["EE>57EI7%H=:_+M6V.J/VAY M\=/NN)3(B@&CCZ#MT*"S&4#+[*3E)P9,=!TJIJKGE.M#LK]+<(I[KDB;P_BM MMKXBS$*W;IWN^=G6+KLQ!>Y/26?%$G\QRE_6I\4C/+FFNJ&:54E5F M7UTQV]'.F6'JU")UAX/Y4!MF;\SS Y[M-*=4EQH2$ TKGQ..4$&$RW3,Z1K$ M!+Y*06!9!3O+WVTJ09+44]*^Q6 NRX*G.NZHIW(I]=NEAA'^?C#VD:37/)>E M.Y9%70'@A/]2"=MCR1\^_IAQB>(=$@O('&1_CZ6QE&#[00[M00@5"W_\BO5A MR=0D8 E ;XQ(QE>_4]-B MP+X^X\GR]ZTPM#YW"N>?3NA/K7R+>:*RM(];=OET\;!8V-L*TRL4IL.8,%W2 M:2O8;]65';E+LKY;)_U.H?ZU:Y5^2K+63!H5LX-4M0B=R\7]_&'NGG(&?_#G M7>3N/]SS>UO*X"L '4X<.62<_.-Q4X GJC(VQWV>]1$ 9\R,+A7OGDY!?[=6 MOA1(D2%U9S0R!=9-^E#.Z8^&E/@BOB7]LY"^E>EF>AD%87/D6LX,E&%!_[BM M(6TGL\*&N>G(*A]]8_(?&YDD6+>R%6,K6\TP.!,B^.O,M%D^>57[,BH?-O]N M>#;X55AZG5IA: M2V)J'?[9X9?.Q$YF:;/>R9W_W9Z.W(>%8&MXNI@NRM%RJMKB8P!Z#3=W5_8E M$P54K>,=?@&!'JS2:V+*0=N=&?;_\0ZWGC>F3 8J@O9A+E6M@Z3 R+9)UZ"^ MDCLO)6%^X0 XUM^FNSZ6YH.O-:F;>\9T[RD8&9LQBE0^52T7P-5D1V@'D'RO:G,W69@]C-V. P;T1;6 M.*/K=?:,[4,$4C_YYMP\4F>CZ:WP\+?1;^4?"O3Q/%'98B,# I OEW/IP=N.-S&(SY=__.BSD#XZ$ M)IG%7"09L17-=C%6M3S,AA,*,@"DW]J:5XC90VQ-.UM[ \)_"KX8X\'^&%>N M&82IU%]W0>P'Q"\U@0@;?2YB41'6(VSE_YDQ^\<3TAS,GA*U^I#IMYH<,D)= M\+C!J<**D[XS)7UF.1/D-[Y$J2"'Z8]D8%IH\TP!!E R4 Z#2 =$8>19DMK, M\80U(P*41PQFJF?0P>D#"GYFPR_,BNZ\*B73J#T+WPT<"R;'?A@%F)BM$I6- MI/];VX!],+BY3&'/M)_4RBWY7_N!__6%FQ)$&A.DGAVDX42R$V8+=WARR?;D M#7MTQ53?<2Q&;77,+^J>)8(1]=%**#7E@U+IZ$RVO(>O]#%S> M?&8L6Y-"8$UZCF7J(*7VS3FLJ+"L6LFFI/2!#LI?O;[!'U8!=A]3L@I#U([L M;80=6>"H0!P%B*X:D7R)IO.%B!V)%4W/K4@IE_%;;@W)2V+S*JB;R9)U*>D+ MSM CP%/QZAP/NMZ\,QBL2Q,5Y=GYQ;CW]WGCT:GXM69E/2Q1\[*_$>8%<$WK M$63OY:_D2T:ZL--_=S]CX[?=FIN7Q/:W:FYRR>:F)83'^ ^-3N<#NQC/QJTK M_=$UI?_?:NQ+$S-B/U$4BS9]M1XV"8Z(K)3!L;X<^HM#N]9KU#[YMH6<4W[+ M)#D[J]]#C+8QX>M#K67C87_)M/Z,Z%CD@0#<@C? U"&LI0H,4Q"8EX$$W MQ0UW)G*(R087JS*H( 8;F+9_+M[?DLWMA2'CTGZL?_U,4=M!XAX*(>BXO\C$6AGRXDC)5TIPT)!\7LQ:)?9-C,1C+SI<@I-V^&\BD1:P82 MIRU)W++9;<8J\\->'U2GNM\GV?J:UOE)NW3Y\?"_3[^]>@3$R8&C7&!O#A#6=C4T _L-;4UG$CG.KJ0P (*7Y8_$S$C)?5T7#S^S ,4X M@,@=0>]O'N[>0"^%J8IQ5JE^1\)I":M]Q?9%+CN:NU[.;HZC 4/"X77ZI$VS].4]S(H;NNF"6&-/()N2Y # M[GU/$E!US%9Q-L XB8 :$X" H^:PJ0N/@CH80%!G'$'6!IX$6^U?E(M9+0-Z M"\^2(D.^,'+#;,:I9!#1+,[.)LA M/4\?:NL;1(^SRJ$C6(2@/M%#VZ5LDFH_=M 6<5/'/'V@WV*E%H=8K\P9

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�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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001661053 2024-03-06 2024-03-06 iso4217:USD shares iso4217:USD shares false 0001661053 8-K 2024-03-06 enVVeno Medical Corporation DE 001-38325 33-0936180 70 Doppler Irvine CA 92618 (949) 261-2900 false false false false Common Stock, par value $0.00001 per share NVNO NASDAQ false